Little River, South Carolina – (work wire) – PCT LTD (OTC Pink: PCTL).
On Monday, May 23, the Environmental Protection Agency released its Guidelines for Viral Pathogens (EVP) in response to recent cases of monkeypox in the United States.
When rare or new viruses cause outbreaks, there may be few, if any, disinfectants that have been registered for use against that specific pathogen. To prepare for such situations, the US Environmental Protection Agency (EPA) in 2016 created the Emerging Viral Pathogens (EVP) Guidelines. The EPA now considers monkeypox virus an emerging viral pathogen, and it is only the third pathogen to be placed on this list after SARS-Cov-2 and rabbit hemorrhagic disease virus (RHDV2).
Monkeypox virus is caused by monkeypox virus, which is a double-stranded enveloped DNA virus and belongs to a group of viruses that are more susceptible to disinfectants than other types of viruses. Although there are no disinfectants registered for use against monkeypox, all products with EVP claims have been tested against viruses that are much harder to kill than monkeypox. The Environmental Protection Agency expects that products on the list of disinfectants for emerging viral pathogens will kill monkeypox when used according to label directions. Initially, the CDC recommended the use of a disinfectant on the EPA’s List N for SARS-Cov-2. List N has been compiled by the Environmental Protection Agency (EPA) for efficacy against SARS-Cov-2 of disinfectants that either already have voluntary registration with an emerging viral pathogen claim because they demonstrate efficacy against viruses that are difficult to inactivate (such as large or small inactivated viruses). enveloped), you do not have voluntary registration with an emerging viral pathogen, but demonstrate eligibility because they have a large or small claim to non-enveloped viruses, or have demonstrated efficacy against any member of the coronavirus family.
On May 26, the Environmental Protection Agency released its Disinfectants for Emerging Viral Pathogens (EVPs): Q List. Since the Monkey Pox virus is an envelope virus that is more susceptible to disinfectants than other types of viruses, every disinfectant on the Q List has demonstrated effectiveness against a stronger virus and meets the minimum of effectiveness against the Monkey Pox virus. As part of the launch of the Q List, in addition to referring to the various virus categories as “enveloped,” “large and non-enveloped,” and “small and non-enveloped,” the EPA EVP Handbook divides viruses into three categories:
Level 1: Encapsulated viruses are the easiest to deactivate. When disinfectants damage their lipid coating, the virus is no longer contagious.
Level 2: Large non-enveloped viruses are encapsulated in protein capsules which makes inactivation more difficult compared to enveloped viruses.
Level 3: Small, non-enveloped viruses are the hardest to disable. Both protein capsules and their small size make them less susceptible to disinfectants compared to other viruses.
Hydrolyte® meets the highest standards of efficacy against many types of disease-causing families, including healthcare HAI pathogens such as C. diff, MRSA, VREs, CREs, TB, HIV and Norovirus. Hydrolyte® was among the first disinfectants to be added to the EPA N List in March 2020. There are now 605 entries on List N. ) in July 2020. New EPA-specific disinfectants for emerging viral pathogens (EVPs): List Q contains It has 421 Level 1 entries, 353 Level 2 entries, and only 168 Level 3 entries. Hydrolyte® is now on the EPA’s new EVP Q list and is in a small business as a Level 1, 2, and 3 EVP disinfectant. Pre-screened for use on any future emerging viral pathogens including envelope (Tier 1), large, nonenveloped (Tier 2), or small non-enveloped (Tier 3) viruses once they are declared EVP by the Environmental Protection Agency (EPA). As an EVP disinfectant, PCT Corp can make the following claims and off-label statements about expected efficacy in the technical literature distributed to healthcare facilities, physicians, nurses, and public health officials; Websites not related to the label; consumer information services; And social networking sites:
The monkeypox virus causes monkeypox. Hydrolyte® kills similar viruses and therefore can be used against Monkeypox virus when used as directed against Norovirus and Rhinovirus type 16 on hard, non-porous surfaces. See the CDC website at https://www.cdc.gov/poxvirus/monkeypox/index.html for additional information.
Daryl Patterson COO of PCT Corp and Vice President of PCT Corp Healthcare stated:
“Hospitals and other healthcare facilities using PCT Corp Hydrolyte® Disinfectant are already ready to keep their patients and staff safe against Monkeypox virus as they continue to use Hydrolyte® against SARS-Cov-2, the virus that causes Covid-19, and other care-related pathogens.” health care including bacteria such as C. diff and MRSA.”
Hydrolyte® is an activated aqueous solution of hypochlorous acid (HOCl) produced by passing a weak brine solution through an electrolysis cell using chemical activation technology (ECA) to temporarily change the properties of diluted brine into a strong oxidizing agent with antimicrobial properties. Hydrolyte® is produced at approximately neutral pH 6.5 with the predominant antimicrobial agent being hypochlorous acid, a potent and potent form of chlorine derived from natural salt minerals and water and rapidly decomposing completely to brine. Hypochlorous acid kills bacteria. When produced, Hydrolyte® (anolyte solution), contains a minimum of 500 parts per million of available chlorine (FAC).
Hydrolyte® has the lowest EPA Class IV toxicity rating. Does not contain any indication words such as “danger,” “warning,” “warning,” or any EPA precautionary statements such as “use in a well-ventilated area,” “rinse eyes…,” “do not induce vomiting,” “wash your hands before eating or drinking”, etc. Other than the “keep out of children’s reach” which is required for all sanitizers. Hydrolyte® does not require the use of gloves, goggles, gowns, respirators, or other personal protective equipment for handling, although it is recommended, especially for infectious pathogens. Tested in accordance with the AOAC Germicidal Spray Product Test for Disinfectants and meets surface disinfection recommendations per OSHA standards for bloodborne pathogens. This makes it ideal for spraying not only in healthcare visiting areas and patient rooms, but also in hotel lobbies, common areas, schools, day care, airport passenger terminals, airplanes, transit vehicles, shuttle buses, and retail spaces without causing any health problems or exposure to patients, visitors, customers or Guests, passengers or your employees while applying the product. Hydrolyte® is free of alcohol, dyes, fragrances, phenols, VOCs, harsh fumes or harsh chemicals and leaves no sticky, greasy, flammable, harmful, harsh or chemical chemical residues on surfaces after evaporation. Hydrolyte® kills Clostridium difficile in hospital patient rooms, nursing homes, and bathrooms, yet is sufficient for use in neonatal intensive care units and gentle for use in newborn incubators and toys.
About PCT LTD:
PCT LTD (“PCTL”) focuses its business on acquiring, developing and providing sustainable and environmentally safe technologies for disinfection, cleaning and traceability. The company holds rights to innovative products and technologies, which are marketed through its subsidiary operating company, Paradigm Convergence Technologies Corporation (PCT Corp). The company has established entry into its target markets with commercially viable products in the US and now continues to gain market share in the US and UK
This press release contains “forward-looking statements” as defined in Section 27A of the Securities Exchange Act of 1933, as amended, and Section 21B of the Securities Exchange Act of 1934, as amended. Any statements that express or include discussions regarding future predictions, expectations, beliefs, plans, expectations, objectives, goals, assumptions, events or performance are not statements of historical facts and may be “forward-looking statements”.
These statements are based on expectations, estimates and expectations at the time the statements were made that involve a number of risks and uncertainties, and could cause actual results or events to differ materially from those currently expected. Such statements involve risks and uncertainties, including but not limited to: the ability of the PCTL to raise sufficient funds to meet its working capital requirements; PCTL’s ability to implement its business plan; The expected results of business contracts in relation to revenue; and any other effects arising from the information disclosed above; risks and implications of legal and administrative procedures and government regulation; future financial and operating results; Competition; General economic conditions and the ability to manage and continue growth. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, actual results may differ materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements made by PCTL in this press release include market conditions and those set forth in reports or documents you file from time to time with the Securities and Exchange Commission. The PCTL does not undertake to revise or update this data to reflect current events or conditions after the date of this Contract or to reflect the occurrence of unforeseen events.